AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01453166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart prevent control Meal monthly
Description: received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A and B, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts) at the same of group B. The difference of group C was the number of sessions with the dietician. That happen monthly in person sessions.
Study NCT01110057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match GW856553
Study NCT01110057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS856553
Description: GW586553 7.5mg bid
Study NCT03144167 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Analysis of spectroscopic biomarkers of proliferation for six-month survival
Description: Analysis of spectroscopic biomarkers of proliferation, glial reaction, infiltration and glutaminergic metabolism or glycolytic metabolism for six-month survival
Study NCT00998257 — intervention group
Intervention type: DRUG
Intervention: EE20/DRSP (YAZ, BAY86-5300)
Description: Patients under daily life treatment with YAZ according to local drug information.
Study NCT00163644 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: aereobic plus resisted exercise
Study NCT00163644 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: aerobic plus active exercise
Study NCT00163644 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No formal exercise plus phone calls
Study NCT03577899 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5 mg Conbercept Intravitreal Injection
Description: Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) for a total of 92 weeks treatment in the study eye.
Study NCT03577899 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1.0 mg Conbercept Intravitreal Injection
Description: Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) for a total of 92 weeks treatment in the study eye.
Study NCT03577899 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 2.0 mg Aflibercept Intravitreal Injection
Description: Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) for a total of 92 weeks of treatment in the study eye.
Study NCT00812955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-143
Description: Once daily for 8 weeks
Study NCT00812955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: Once daily for 8 weeks simvastatin capsules 40 mg
Study NCT03066206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poziotinib
Description: Given PO
Study NCT04284137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified FE-SaLiR
Description: Participants will attend a 60-minute exercise program (modified Wu Qin Xi and Ba Duan Jin) in a non-clinical community setting twice a week and will perform the exercises at home using guided video up to three times a week. Text messages will be sent to remind the participants to do the exercise at home.
Study NCT04284137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unmodified Chinese Medicine Exercise
Description: Participants will attend a 60-minute exercise program (Wu Qin Xi and Ba Duan Jin published by the General Administration of Sport of China) in a non-clinical community setting twice a week and will be expected to practice exercise at home using guided video up to three times a week. Text messages will be sent to remind the participants to do the exercise at home.
Study NCT04284137 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Participants will attend a 60-minute health education program once a week.
Study NCT02113319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: dasatinib 50 mg and 20 mg During one year
Study NCT02234362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vortioxetine
Description: Eligible subjects will initiate the treatment with 5 mg/day for two days and then 10 mg/day starting on Day 3. The dosage may be increased from 10 mg/day to 15 mg/day at Visit 2 or Visit 3. At Visit 4, the dosage may again be increased from 10 to 15 mg/day or from 15 to 20 mg/day, based on patient response and tolerability.
Study NCT01263327 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV 16/18
Description: Participants would intramuscularly receive 90mcg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
Study NCT03082924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control group
Description: Neither cycle training nor inspiratory muscle training.
Study NCT00239837 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Middle School Success Intervention (MSS)
Description: This is a 10-month, psychosocial intervention for foster parents and girls, with administration of the intervention beginning the summer before entry into middle school. The intervention consists of: (1) six summer Pride groups for the girls, (2) six summer parenting intervention sessions for the foster parents; (3) weekly foster parent training and support sessions for foster parents during the first year of middle school; and (4) weekly individual skills training for the girls during the first year of middle school.
Study NCT04627116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tecarfarin
Description: Ten (10) healthy Chinese subjects received once-daily doses of Tecarfarin on fasting every morning for 14 days.
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipramine
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipramine
Study NCT04195100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pilocarpine Ophthalmic Solution
Description: 1. low dose pilocarpine = 3 x 2.0 mg = 3 x 2 drops of pilocarpine 20.0 mg/ml (2%) per day~2. high dose pilocarpine = 3 x 5.0 mg = 3 x 5 drops of pilocarpine 20.0 mg/ml (2%) per day
Study NCT00743457 — intervention group
Intervention type: DEVICE
Intervention: Ocular Ultrasound
Description: B-mode ultrasound of the eye with 90 and 30 degree view of optic nerve sheath
Study NCT03255993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127 50mg
Description: SPH3127 50mg
Study NCT03255993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127 100mg
Description: SPH3127 100mg
Study NCT03255993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching to SPH3127 50mg
Description: Placebo matching to SPH3127 50mg
Study NCT03255993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching to SPH3127 100mg
Description: Placebo matching to SPH3127 100mg
Study NCT00176241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 2000-3000mg/m2 IV on days 1 \& 15
Study NCT00176241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 150 mg/m2 IV on days 1 \& 15
Study NCT00176241 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: 50-80 cGy on days 1,2,15,16
Study NCT00718666 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: One dose, as intramuscular injection
Study NCT03082924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calibrated cycle ergometer
Description: The most common device to perform cycle training is calibrated cycle ergometer.
Study NCT03082924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold loading device
Description: Threshold loading device is used to perform inspiratory muscle training.
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amitriptyline
Study NCT00835419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P276-00
Description: P276-00 -small molecule Cdk 4-D1, Cdk1-B and Cdk9-T inhibitor
Study NCT01999166 — intervention group
Intervention type: RADIATION
Intervention: radiography (X-ray)
Study NCT01999166 — intervention group
Intervention type: GENETIC
Intervention: DNA sampling
Study NCT03060083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low nicotine content (VLNC) cigarettes and nicotine replacement therapy (NRT)
Description: Participants will switch to very low nicotine content (VLNC) cigarettes with the aid of nicotine replacement therapy (NRT)
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amitriptyline
Study NCT03814330 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: State-Trait Anxiety Inventory
Description: State-Trait Anxiety Inventory measures state anxiety levels and is an easy-to-implement inventory that the individual can answer on his/her own. State-Trait Anxiety Inventory determines how the individual feels himself / herself at a given moment and under certain conditions. It is widely used in preoperative anxiety measurement
Study NCT03814330 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: State-Trait Anxiety Inventory
Description: State-Trait Anxiety Inventory measures state anxiety levels and is an easy-to-implement inventory that the individual can answer on his/her own. State-Trait Anxiety Inventory determines how the individual feels himself / herself at a given moment and under certain conditions. It is widely used in preoperative anxiety measurement
Study NCT03814330 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Quality of Recovery Score
Description: Recovery Quality Score-40 (Quality of Recovery Score) and is used to measure the quality of postoperative recovery. This form consists 40 items and is divided into 5 subgroups according to various aspects of the improvement. There are a total of 40 items, 9 related to emotional state, 12 related to physical comfort, 7 related to psychological support, 5 related to physical independence and 7 items related to pain. The questionnaire is scored as a minimum of 40 to a maximum of 200.
Study NCT03814330 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Quality of Recovery Score
Description: Recovery Quality Score-40 (Quality of Recovery Score) and is used to measure the quality of postoperative recovery. This form consists 40 items and is divided into 5 subgroups according to various aspects of the improvement. There are a total of 40 items, 9 related to emotional state, 12 related to physical comfort, 7 related to psychological support, 5 related to physical independence and 7 items related to pain. The questionnaire is scored as a minimum of 40 to a maximum of 200.
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomipramine
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomipramine
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nortriptyline
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nortriptyline
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trazodone
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trazodone
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulpiride
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulpiride
Study NCT02697877 — intervention group
Intervention type: DRUG
Intervention: Regadenoson
Study NCT02990234 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Capsular Repair
Study NCT02990234 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: No Capsular Repair
Study NCT03892564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MC2-01 Cream, irradiation
Description: One application of MC2-01 Cream, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
Study NCT03892564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MC2-01 Cream, no irradiation
Description: One application of MC2-01 Cream. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
Study NCT03892564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MC2-01 vehicle, irradiation
Description: One application of MC2-01 vehicle, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
Study NCT03892564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MC2-01 vehicle, no irradiation
Description: One application of MC2-01 vehicle. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
Study NCT03892564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control, irradiation
Description: Untreated, irradiated site. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
Study NCT02079844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Roflumilast tablets
Study NCT02079844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Roflumilast placebo-matching tablets
Study NCT02079844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second generation antipsychotic
Description: Second Generation Antipsychotic (SGA) medication for standard of care therapy will be sourced and managed locally by the site.
Study NCT02740400 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS-GS
Description: The equipment for EBUS-GS includes super-thin bronchoscope BF-P260F, endobronchial ultrasonic system EU-M30S, ultrasonic probe UM-S20-17S, and guided sheath kit K201. All facilities are provided by Olympus Co. The EBUS-GS procedure was performed by thoracic surgeons. The patient was in supine position, under general anesthesia, and provided ventilatation through laryngeal mask. First, the operator placed super-thin bronchoscope into the bronchus of interest, inserted the probe covered with GS through a work channel. Later, adjusted the bronchoscope and probe to obtain classical ultrasonic graphs. The assistant fixed the bronchoscope, pulled the probe out, and placed the brush and biopsy forceps, respectively, through the GS. This process was assisted using x-ray fluoroscope or not.
Study NCT02740400 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT-TTNB
Description: The devices for CT-TTNB includes Lightspeed VCT spiral CT(GE co.) and Quickcore(COOK Co.) biopsy kit. The kit includes a sheath(5cm in length and 16G in outer diameter) and a automatic biopsy needle(15cm in length and 18G in outer diameter). The patient stays in supine, prone or lateral position according to the lesion's location. The first chest CT scan is performed to confirm the location of the lesion and make an optimal entry point. Then, after sterilization and 2% lidocaine local anesthesia, the sheath is stabbed into chest wall through the entry point. The second CT scan is performed to make sure that the sheath stays in proper angle and depth. The operator places the needle through the sheath and enter the lesion. Then fire the biopsy needle and repeat the procedure twice or third time. The last CT scan is conducted to determine whether pneumothorax or hemorrhage occurred.
Study NCT03855007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod
Description: Iguratimod tablet，25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
Study NCT03855007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: MTX，7.5mg to 15mg, po, once per week (Qw) prescribed if needed and adjusted due to patient response or unacceptable toxicity develops.
Study NCT03855007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCQ
Description: HCQ，200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.
Study NCT03855007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pred
Description: Pred, 5-15mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response
Study NCT03489187 — intervention group
Intervention type: DEVICE
Intervention: Visualase Thermal Therapy System
Description: Patients who have previously received treatment with VTTS when used as intended.
Study NCT01298934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Description: Dose escalation study starting at 20mg by mouth three times a week, given weekly for 24 weeks in the phase I portion of the study.
Study NCT00750620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178
Description: oral
Study NCT01957124 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRF (Platelet-Rich Fibrin)
Study NCT03082924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calibrated cycle ergometer and threshold loading device
Description: Combined cycle training and inspiratory muscle training.The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
Study NCT01905540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSP-004184AQ
Description: Magnesium salt
Study NCT01905540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSP-004184SS
Description: Disodium salt
Study NCT02283034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The CPRmeter
Description: Feedback device - 1
Study NCT01029587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Eculizumab will be administered by intravenous infusion. Eculizumab will be administered at a dose of 1200mg by intravenous (IV) infusion on the day of or on the day prior to kidney transplantation, and at a dose of 900mg IV on post-operative day 1. Subsequently, the post-operative dosing regimen would be comprised of an induction phase of weekly doses of 900mg IV per dose followed by a maintenance phase of every other week dosing of 1200mg IV per dose. The weekly induction dosing regimen would begin on postoperative day 8, and would continue for three doses (specifically, doses of 900mg IV would be given on postoperative days 8, 15, and 22). The maintenance phase of dosing would begin with a dose of 1200mg on postoperative day 29, and would continue for a total of 5 doses (specifically, doses of 1200mg IV would be given on postoperative days 29, 43, 47, 72, and 85). In most cases, eculizumab would be discontinued after the 5th maintenance dose.
Study NCT03133234 — intervention group
Intervention type: DRUG
Intervention: osimertinib
Description: Oral dose of 80mg once daily
Study NCT01608347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMWH+Folic acid
Description: Patients will receive a fixed dose of 40 mg of enoxaparin subcutaneous daily. Treatment will start once positive pregnancy test and will be continued until abortion or delivery (if premature), or 37 weeks of pregnancy. Additionally, 500 micrograms Folic acid tablet once daily will be started once positive pregnancy test and continues until 13 weeks' of gestation.
Study NCT01608347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Folic acid 500 micrograms daily once positive pregnancy test until the 13th week of pregnancy or abortion
Study NCT02283034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The PocketCPR
Description: Feedback device - 2
Study NCT03060083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduce cigarettes per day (CPD) with nicotine replacement therapy (NRT)
Description: Participants will reduce cigarettes per day (CPD) with the aid of nicotine replacement therapy (NRT)
Study NCT01616888 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTA with drug eluting balloon with paclitaxel
Description: Angioplasty with drug eluting balloon with paclitaxel on femoropopliteal arteries
Study NCT04410198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Roxadustat will be administered per dose and schedule specified in the arm description.
Study NCT00507416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib bolus intravenous (IV) injection
Study NCT02515305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin and Benzoyl Peroxide Gel (combination)
Study NCT02515305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin and Benzoyl Peroxide Gel (Reference) (combination)
Study NCT02515305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel (combination)
Study NCT00903162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide
Description: Given intramuscularly beginning on day 1 and then either 7.5 mg every month or 22.5 mg every 3 months for two years